Movement Alert｜Haixi New Drug Rises 5.37% in Regular Trading, Recovery Extends on Strong Annual Results and Broker Coverage

Market Focus05-20

On May 20, Haixi New Drug (02637.HK) rose 5.37% in regular trading, trading at 248.2 HKD/share, with trading volume of approximately 28.97 million HKD. The stock extended its rebound after fully digesting profit-taking pressure during the May 13-15 pullback.

On the news front, the company's annual report showed revenue of RMB 5.82 billion, up 24.79% year-over-year, with net profit attributable to shareholders reaching RMB 1.77 billion, a 30.09% increase. Gross margin improved to 83.38%. Multiple brokerages including Guohai Securities, Huayuan Securities, and Shenwan Hongyuan initiated or maintained Buy ratings, with target prices ranging from 298 to 339 HKD, implying significant upside from current levels.

Notably, the broader Pharmaceuticals sector traded weak on the day, with CSPC Pharma down 1.48%, Hansoh Pharma down 1.65%, Hengrui Pharma down 0.65%, and Simcere Pharma down 5.27%, highlighting the stock's relative outperformance against sector headwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1161926855?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-20 14:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161926855","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Haixi New Drug Rises 5.37% in Regular Trading, Recovery Extends on Strong Annual Results and Broker Coverage","media":"Market Focus","content":"<p><p>On May 20, Haixi New Drug (02637.HK) rose 5.37% in regular trading, trading at 248.2 HKD/share, with trading volume of approximately 28.97 million HKD. The stock extended its rebound after fully digesting profit-taking pressure during the May 13-15 pullback.</p><p>On the news front, the company's annual report showed revenue of RMB 5.82 billion, up 24.79% year-over-year, with net profit attributable to shareholders reaching RMB 1.77 billion, a 30.09% increase. Gross margin improved to 83.38%. Multiple brokerages including Guohai Securities, Huayuan Securities, and Shenwan Hongyuan initiated or maintained Buy ratings, with target prices ranging from 298 to 339 HKD, implying significant upside from current levels.</p><p>Notably, the broader Pharmaceuticals sector traded weak on the day, with CSPC Pharma down 1.48%, Hansoh Pharma down 1.65%, Hengrui Pharma down 0.65%, and Simcere Pharma down 5.27%, highlighting the stock's relative outperformance against sector headwinds.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Haixi New Drug Rises 5.37% in Regular Trading, Recovery Extends on Strong Annual Results and Broker Coverage</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Haixi New Drug Rises 5.37% in Regular Trading, Recovery Extends on Strong Annual Results and Broker Coverage\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-20 14:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 20, Haixi New Drug (02637.HK) rose 5.37% in regular trading, trading at 248.2 HKD/share, with trading volume of approximately 28.97 million HKD. The stock extended its rebound after fully digesting profit-taking pressure during the May 13-15 pullback.</p><p>On the news front, the company's annual report showed revenue of RMB 5.82 billion, up 24.79% year-over-year, with net profit attributable to shareholders reaching RMB 1.77 billion, a 30.09% increase. Gross margin improved to 83.38%. Multiple brokerages including Guohai Securities, Huayuan Securities, and Shenwan Hongyuan initiated or maintained Buy ratings, with target prices ranging from 298 to 339 HKD, implying significant upside from current levels.</p><p>Notably, the broader Pharmaceuticals sector traded weak on the day, with CSPC Pharma down 1.48%, Hansoh Pharma down 1.65%, Hengrui Pharma down 0.65%, and Simcere Pharma down 5.27%, highlighting the stock's relative outperformance against sector headwinds.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02637","symbol_name":"海西新药","start_time":0,"source_url":"","article_id":"1161926855","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161926855","pubTimestamp":1779259395,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 20, Haixi New Drug (02637.HK) rose 5.37% in regular trading, trading at 248.2 HKD/share, with trading volume of approximately 28.97 million HKD. The stock extended its rebound after fully...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02637":"海西新药"},"translate_title":"动感快讯|海西新药常规交易涨5.37%强劲年度业绩及券商覆盖下复苏延伸","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02637":1},"content_text":"On May 20, Haixi New Drug (02637.HK) rose 5.37% in regular trading, trading at 248.2 HKD/share, with trading volume of approximately 28.97 million HKD. The stock extended its rebound after fully digesting profit-taking pressure during the May 13-15 pullback.On the news front, the company's annual report showed revenue of RMB 5.82 billion, up 24.79% year-over-year, with net profit attributable to shareholders reaching RMB 1.77 billion, a 30.09% increase. Gross margin improved to 83.38%. Multiple brokerages including Guohai Securities, Huayuan Securities, and Shenwan Hongyuan initiated or maintained Buy ratings, with target prices ranging from 298 to 339 HKD, implying significant upside from current levels.Notably, the broader Pharmaceuticals sector traded weak on the day, with CSPC Pharma down 1.48%, Hansoh Pharma down 1.65%, Hengrui Pharma down 0.65%, and Simcere Pharma down 5.27%, highlighting the stock's relative outperformance against sector headwinds.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1161926855","isCrawlerRequest":true}